Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Shares Sold by Jacobs Levy Equity Management Inc.

Jacobs Levy Equity Management Inc. lowered its holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) by 67.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 470,726 shares of the biopharmaceutical company's stock after selling 959,807 shares during the quarter. Jacobs Levy Equity Management Inc. owned 0.81% of Vanda Pharmaceuticals worth $2,255,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently bought and sold shares of VNDA. Barclays PLC boosted its stake in shares of Vanda Pharmaceuticals by 128.2% during the 3rd quarter. Barclays PLC now owns 154,297 shares of the biopharmaceutical company's stock worth $722,000 after acquiring an additional 86,677 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in Vanda Pharmaceuticals by 16.1% during the third quarter. JPMorgan Chase & Co. now owns 160,722 shares of the biopharmaceutical company's stock worth $754,000 after purchasing an additional 22,249 shares during the last quarter. SG Americas Securities LLC boosted its position in Vanda Pharmaceuticals by 26.8% during the fourth quarter. SG Americas Securities LLC now owns 25,861 shares of the biopharmaceutical company's stock worth $124,000 after purchasing an additional 5,459 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its position in Vanda Pharmaceuticals by 4.9% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 819,382 shares of the biopharmaceutical company's stock worth $3,925,000 after purchasing an additional 38,449 shares in the last quarter. Finally, Monaco Asset Management SAM grew its holdings in Vanda Pharmaceuticals by 92.8% in the fourth quarter. Monaco Asset Management SAM now owns 392,262 shares of the biopharmaceutical company's stock valued at $1,879,000 after purchasing an additional 188,836 shares during the last quarter. Institutional investors and hedge funds own 88.14% of the company's stock.

Insider Buying and Selling

In other Vanda Pharmaceuticals news, CEO Mihael Hristos Polymeropoulos purchased 10,000 shares of the firm's stock in a transaction on Tuesday, February 25th. The shares were purchased at an average cost of $4.46 per share, with a total value of $44,600.00. Following the purchase, the chief executive officer now owns 2,331,730 shares in the company, valued at approximately $10,399,515.80. This represents a 0.43% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Over the last 90 days, insiders have bought 52,000 shares of company stock worth $235,580. 8.90% of the stock is owned by insiders.

Vanda Pharmaceuticals Stock Performance

VNDA stock traded down $0.04 during trading on Wednesday, hitting $4.41. The stock had a trading volume of 136,596 shares, compared to its average volume of 720,804. The stock has a market cap of $259.60 million, a price-to-earnings ratio of -13.77 and a beta of 0.69. The company's 50 day moving average price is $4.42 and its two-hundred day moving average price is $4.63. Vanda Pharmaceuticals Inc. has a 1-year low of $3.81 and a 1-year high of $6.75.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported ($0.50) EPS for the quarter, topping analysts' consensus estimates of ($0.55) by $0.05. The business had revenue of $50.04 million during the quarter, compared to the consensus estimate of $45.13 million. Vanda Pharmaceuticals had a negative net margin of 9.51% and a negative return on equity of 3.49%. As a group, sell-side analysts forecast that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on VNDA shares. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $13.00 price target on shares of Vanda Pharmaceuticals in a research note on Wednesday, May 14th. HC Wainwright reaffirmed a "buy" rating and issued a $20.00 target price on shares of Vanda Pharmaceuticals in a research note on Wednesday, May 7th. Finally, StockNews.com started coverage on Vanda Pharmaceuticals in a research report on Wednesday, February 5th. They set a "hold" rating for the company.

Vanda Pharmaceuticals Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.